CClinicalTrials.gg
RecruitingNCT06038318Updated Dec 29, 2025

Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer

An interventional study of PRISM Program Video Coach and PRISM Program Text Coach in Stress and Anxiety, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 12 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Oct 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Study summary

The goal of this study is to find the best way to help participants and families manage the stress of facing a serious illness and be better able to "bounce back" or be resilient after a difficult situation. Participants will take part in the "Promoting Resilience in Stress Management" PRISM program, which is designed to provide skills to change or improve the impact of stress in everyday life.

The name of the intervention used in this research study is:

-PRISM (a mobile app program comprised of 6 sessions of skills-based, manualized resilience education)

Read the detailed description

In this sequential, multiple assignment, randomized trial participants will be randomly selected to participate in PRISM program sessions with a trained research coach either by text or by video sessions, or participants will use the PRISM mobile app program in a self-guided way. Randomization means the group participants are placed in will be decided by chance. All groups will continue to receive all the same care from primary medical, social work, and other care teams.

In this two-stage study, participants will be randomly assigned to either the "app-only" (20% chance), "text" (40% chance) or "video" (40% chance) groups for the first stage. In the second stage, participants may be re-randomized again to the "app-only," or "text," groups, or will be referred to a specialty psychosocial support, social worker or counselor, based on responses to questionnaires. Participants randomized to the "app-only" group in the first stage will not be re-randomized.

The research study procedures include screening for eligibility and completion of questionnaires.

Participation in this research study is expected to last for up to 6 months.

It is expected about 325 people will take part in this research study.

The National Institute for Health (NIH) is funding this research study.

02

Conditions studied

  • Stress
  • Anxiety

Browse trials for

Keywords

  • Stress Management
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's planned enrollment of 325 is above the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.

Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Participants that have completed their main cancer-directed therapy at one of the study sites affiliated centers who meet all the eligibility criteria will be eligible for participation in this study.

Inclusion Criteria:

  • All genders ≥ 12 and ≤ 25 years of age at baseline
  • Participant is able to speak English or Spanish language (for PRISM sessions)
  • Participant is able to read English or Spanish language (for completion of surveys)
  • Participant is cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
325 participants (estimated)

Study arms

  • Experimental
    PRISM Program Mobile App

    Participants will be randomized to "app-only" group and will complete: * Baseline questionnaire. * mPRISM App self guided modules * 3 month questionnaire. * mPRISM App self guided modules until final survey at 6 months and end of participation.

    Behavioral: mPRISM Program App

  • Active comparator
    PRISM Program Video Coach

    Participants will be randomized to "video" group and will complete: * Baseline questionnaire. * PRISM sessions. * 3 month questionnaire with re-randomization to either "app-only" or "text" groups or referral to specialty psychosocial support. * After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation.

    Behavioral: PRISM Program Video Coach · Behavioral: mPRISM Program App

  • Active comparator
    PRISM Program Text Coach

    Participants will be randomized to "text" group and will complete: * Baseline questionnaire. * PRISM sessions. * 3 month questionnaire with re-randomization to "app-only," "text," or "video" groups. * After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation.

    Behavioral: PRISM Program Text Coach · Behavioral: mPRISM Program App

Interventions

  • BehavioralPRISM Program Video Coach

    A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.

    Also known as: Promoting Resilience in Stress Management

  • BehavioralPRISM Program Text Coach

    A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.

    Also known as: Promoting Resilience in Stress Management

  • BehavioralmPRISM Program App

    6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.

    Also known as: Promoting Resilience in Stress Management

06

What researchers measure

Primary outcomes

  1. Connor Davidson Resilience Scale (CDRISC-10) Score

    Assessed by the CDRISC-10, a 10-item measures consisting of a 5-point Likert scale with answers ranging from 0 (not true at all) to 4 (true nearly all the time) for a total of 40 points. Higher scores reflect greater resilience. Evaluation will be based on the scores of the video and text cohorts vs. the self-guided cohort.

    Time frame: At 6 months

Secondary outcomes

  1. CDRISC-10 Score for App-Only Cohort Responders

    Assessed by the CDRISC-10, a 10-item measures consisting of a 5-point Likert scale with answers ranging from 0 (not true at all) to 4 (true nearly all the time) for a total of 40 points. Higher scores reflect greater resilience. Participant "responders" are defined as having sustained CDRISC scores \>29 after PRISM sessions or increased by \>2 points at the timepoints.

    Time frame: 3 months

  2. CDRISC-10 Score for Text Coach Cohort Responders

    Assessed by the CDRISC-10, a 10-item measures consisting of a 5-point Likert scale with answers ranging from 0 (not true at all) to 4 (true nearly all the time) for a total of 40 points. Higher scores reflect greater resilience. Participant "responders" are defined as having sustained CDRISC scores \>29 after PRISM sessions or increased by \>2 points at the timepoints.

    Time frame: 3 months

  3. Change in HOPE Scale Score

    Assessed by the HOPE Scale, a 12-item measures scored on an 8-point Likert scale with answers ranging from 1 "Definitely False" to 8 "Definitely True" for a total score of 96. A higher score implies a greater level of hopeful thought patterns.

    Time frame: At Baseline, 3 months, and 6 months

  4. Change in Adolescent Participant Quality of Life Total Score

    Assessed by the Pediatric Quality of Life (PedsQL) Generic Core Scales Short Form (SF15) (Teen or Child Report) and PedsQL Cancer Module (Child or Teen Report) scales, 42-items to evaluate health-related quality of life. Items are rated on a 5-point Likert scale with answers ranging from 0 "Never" to 4 "Almost Always" for a score range of 0 - 100. A higher score represents better health-related quality of life.

    Time frame: At Baseline, 3 months, and 6 months

  5. Change in Young Adult Participant Quality of Life Total Score

    Assessed by the Pediatric Quality of Life (PedsQL) Generic Core Scales Short Form (SF15) Young Adult Report and PedsQL Cancer Module Young Adult Report scales, 42-items to evaluate health-related quality of life. Items are rated on a 5-point Likert scale with answers ranging from 0 "Never" to 4 "Almost Always" for a score range of 0 - 100. A higher score represents better health-related quality of life.

    Time frame: At Baseline, 3 months, and 6 months

  6. Change in Kessler-6 Psychological Distress Scale Score

    Assessed by the Kessler-6, a 6-item measure for the level of psychological distress in the past month. Responses are scored on a 5-point Likert scare with answers ranging from 0 "None of the time" to 4 "All of the time," and with a total score range of 0 - 4. Scores \> or = 7 suggest "high" distressed and those \> or = 13 meet criteria for serious or debilitating psychological distress.

    Time frame: At Baseline, 3 months, and 6 months

  7. Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score

    Assessed by the HADS-A subscale which is comprised of 7 items. Items are scored 0-3 with a subscale total score range of 0 - 21. A higher scores represents increasing abnormality (or caseness) for anxiety.

    Time frame: At Baseline, 3 months, and 6 months

  8. Change in HADS Depression Subscale Score

    Assessed by the HADS-D subscale score which is comprised of 7 items. Items are scored 0-3 with a subscale total score range of 0 - 21. A higher score represents increasing abnormality (or caseness) for depression.

    Time frame: At Baseline, 3 months, and 6 months

07

Study locations

1 of 2 sites recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038318
Lead sponsor
Dana-Farber Cancer Institute
Collaborators
National Cancer Institute (NCI)
Responsible party
Abby Rosenberg (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Sep 14, 2023
Start date
Oct 16, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Abby Rosenberg, MD
Contact
AbbyR_Rosenberg@DFCI.HARVARD.EDU
206-987-6892
Abby Rosenberg, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion